



## Media Release

# HTX, BiotechGate and partners produce the first, comprehensive Canadian Medtech Ecosystem Database.

*Toronto, August 2014*

An HTX led consortium, recently partnered with Biotechgate in launching a Canadian medtech sector specific database. Access to accurate data on the Canadian medtech sector along with other industry statistics is critical for aligning innovation and with key partners during various stages of product development and adoption. Over 20 medtech databases have been created in Canada over the last decade however, all suffer from single-organization mandates, limited data sets, and atrophy over time due to lack of regular maintenance and updates.

The HTX-led initiative, Medtech RISE, the Registry of Medtech Innovators, Suppliers and Exporters is a nationally focused initiative aimed at consolidating existing siloed databases and fostering local, national and international connectivity between researchers, customers, investors, collaborators, suppliers and world-class medtech companies. The culmination of data gathered through efforts of HTX, along with existing data on the Global Biotechgate database, has given rise to the only up-to-date and comprehensive Canadian medtech sector focused database of its kind. Data on Medtech RISE will be updated bi-annually to maintain relevancy and currency. Currently, Medtech RISE offers access to over 2700 Canadian medtech entities and is publicly accessible at [www.htx.ca](http://www.htx.ca).

"Ontario is home to a vibrant medtech ecosystem, world-class medtech companies and expert R&D capacities. This partnership with Biotechgate will allow visitors to use our database to easily access a broad network of medtech focused organizations. Being a large geographic region, Canada has a number of regional medtech clusters with specific strengths that can now be easily mapped and accessed through the Canadian Medtech Asset Map. We are enthusiastic that this valuable tool will further collaborations and foster visibility of our medtech sector nationally and internationally." Shahira Bhimani, Manager, Strategic Initiatives, HTX.

"We are very happy to welcome HTX and its collaborators to our global Biotechgate network of over 30 worldwide partners. We hope to further increase our reach in Canada and provide medtech stakeholders with another great tool while bringing more visibility, especially for smaller companies" Dr. Patrik Frei, CEO of Venture Valuation.

## About us:

### HTX, The Health Technology Exchange ([www.htx.ca](http://www.htx.ca))

From **Invention through Innovation to International Invoice**, HTX provides non-dilutive project financing to emerging and established Ontario-based companies to develop, produce and commercialize innovative market-leading advanced health technologies. Through the Health Technology Commercialization Program (HTCP) and HTX's MedTech ecosystem support activities, HTX is the leading resource and catalyst for accelerating the growth of Ontario's MedTech industry, and enhancing Canada's position as a global leader in commercializing innovative medical technologies. HTX manages a \$21.4M fund on behalf of the Ontario Ministry of Research and Innovation and is a member of the Canadian Venture Capital Association. The HTCP program has levered over \$70 M in total project funding from industry and strategic partners.



**Biotechgate ([www.biotechgate.com](http://www.biotechgate.com))**

The Biotechgate Database is property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Sciences Database containing over 31'000 company profiles and providing the user with information on life science companies licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database on licensing deals and associated financial information on individual deals.

**Venture Valuation AG ([www.venturevaluation.com](http://www.venturevaluation.com))**

Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging high growth companies in industries such as biotechnology, med-tech and high-tech. Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland, Germany, Canada and Asia, Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries.